

# Human epidermal growth factor receptor-2 gene expression positivity determined by silver in situ hybridization/immunohistochemistry methods and associated factors in a cohort of Sri Lankan patients with gastric adenocarcinoma: a prospective study

Journal of International Medical Research

2023, Vol. 51(2) 1–16

© The Author(s) 2023


Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/03000605231154403

journals.sagepub.com/home/imr



Duminda Subasinghe<sup>1,2</sup> , Nathan Acott<sup>2</sup>,  
Pasyodun Korallage Buddhika Mahesh<sup>3</sup>,  
Sivasuriya Sivaganesh<sup>1</sup>, Sithum Munasinghe<sup>4</sup>,  
Mariyan Priyanthi Kumarasinghe<sup>2</sup>,  
Dharmabandu Nandaveva Samarasekera<sup>1</sup> and  
Menaka Dilani Samarawickrema Lokuhetty<sup>5</sup>

## Abstract

**Objective:** Positive human epidermal growth factor 2 (HER2) expression and its predictive clinicopathological features remain unclear in Sri Lankan gastric cancer (GC) patients.

<sup>1</sup>Department of Surgery, Faculty of Medicine, University of Colombo, University Surgical Unit, The National Hospital of Sri Lanka, Colombo, Sri Lanka

<sup>2</sup>PathWest Laboratory Medicine, Perth, & School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia

<sup>3</sup>Postgraduate Institute of Medicine, University of Colombo, Colombo, Sri Lanka

<sup>4</sup>Translational Health Research Institute, Western Sydney University, Campbelltown Campus, Campbelltown, New South Wales, Australia

<sup>5</sup>Department of Pathology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka

### Corresponding author:

Duminda Subasinghe, Department of Surgery, Faculty of Medicine, University of Colombo, University Surgical Unit, The National Hospital of Sri Lanka, Colombo 00800, Sri Lanka.

Email: dumindas1982.hpb@gmail.com



Here, we aimed to determine GC HER2 status predictors by analyzing associations between clinicopathological features and HER2 expression using immunohistochemistry (IHC) and silver in situ hybridization (SISH).

**Methods:** During this 4-year prospective study, clinicopathological data were collected from participants in the National Hospital of Sri Lanka. HER2 IHC and SISH were performed using commercial reagents. Using chi-square tests, associations of HER2-IHC/SISH with clinicopathological features were analyzed.

**Results:** Overall, 145 GC patients were included, 69 had gastrectomies and 76 had biopsies. Positive HER2 expression by IHC was associated with age <60 years, high T stage (assessed pathologically in resections and radiologically in biopsies), high nuclear grade, tumor necrosis, mitosis >5/high-power field, with additional perineural invasion and lymphovascular invasion in resections. These features, excluding lymphovascular invasion but including male sex, were associated with HER2 expression by SISH.

**Conclusions:** Age <60 years, high nuclear grade, tumor necrosis, and perineural invasion are associated factors of HER2 status. These could be used to triage GC patients for HER2 status testing in limited resource settings where IHC/SISH analysis is costly.

### Keywords

Human epidermal growth factor 2, silver in situ hybridization, immunohistochemistry, gastric carcinoma, diagnosis, clinicopathological factors

Date received: 10 April 2022; accepted: 11 January 2023

## Introduction

Gastric adenocarcinoma (GC) is the fourth most common cancer worldwide, with approximately one million new patients diagnosed annually.<sup>1</sup> It is among the most prevalent cancers in Eastern Asia,<sup>2</sup> with the highest GC incidence reported in the East Asian region and the lowest in the North American region.<sup>3</sup> Because most GCs are diagnosed at an advanced stage, treatment options are generally limited. Therefore, the 5-year survival rate is consistently low, being around 20% in most parts of the world.<sup>4,5</sup> Many GC patients present at an advanced (i.e., metastatic) stage in Sri Lanka.<sup>6,7</sup> Currently, there is no comprehensive screening endoscopy program for detecting early GC, mainly because of its associated high cost relative to the low disease incidence in this resource-constrained setting. Therefore, advanced GC is common,

and treatment of these patients remains a challenge in Sri Lanka.

Targeted therapies have significantly impacted the treatment strategy for many common malignancies. At present, the biology of human epidermal growth factor receptor 2 (HER2)-positive tumors has been established for GC.<sup>8</sup> Trastuzumab, also called Herceptin, is a monoclonal humanized antibody directed against HER2 that has become a pivotal agent for the management of HER2-positive advanced and metastatic GC cases.<sup>9</sup> HER2 testing with targeted treatment would be an important aspect of GC therapy in Sri Lankan patients, with eligible GC patients being those with HER2 gene amplification. An individual's HER2 status can be determined by evaluating HER2 protein overexpression levels by immunohistochemistry (IHC) or HER2 gene amplification by in situ hybridization (ISH).

Resource limited settings have many constraints for performing HER2 silver in situ hybridization (SISH) testing, including its costliness and lack of free availability. Hence, a GC patient's HER2 status would likely be determined by IHC. Therefore, a study to predict HER2 status using clinico-pathological parameters would be significantly helpful for such settings. Here, we examined HER2 protein expression levels by IHC and HER2 gene amplification by SISH in a cohort of Sri Lankan GC patients. The findings were correlated to the clinico-pathological features of the patients to help predict the HER2 status. Overall, this study aimed to assess the potential for predicting HER2 overexpression in GC using clinico-pathological features that are not currently evaluated in Sri Lankan GC patients.

## Methods

### *Study setting and ethics*

This prospective, collaborative study was performed at the Departments of Surgery and Pathology, Faculty of Medicine, University of Colombo, the Department of Pathology, National Hospital of Sri Lanka (NHSL), and the Department of Anatomical Pathology, Pathwest QE II Medical Centre, Perth, Australia. The study was approved by the Ethics Committees of the Faculty of Medicine, University of Colombo (Registration No: EC 11-139) and the NHSL (Reference No: AA/ETH/2012). All participants provided written informed consent before they were included in the study. All patient details were de-identified. The reporting of this study conforms to STROBE guidelines.<sup>10</sup>

### *Study population*

GC patients presenting to the NHSL over 4 years (April 2012 to April 2016) were studied and followed up until December 2017.

All patients underwent upper gastrointestinal endoscopy and biopsy for confirmation of the diagnosis. Patients with gastroesophageal junction (GOJ) cancers were excluded from the study. None of the patients had received neoadjuvant chemotherapy or any other type of treatment prior to biopsy/resection. Only the gastric resection specimen was included for patients who underwent curative surgery following biopsy. The endoscopic biopsy was included for patients with advanced tumors who did not undergo gastric resection. Radiological stage was assessed by contrast enhanced computed tomography of the abdomen and thorax. Radiological data were used to determine the N (nodal enlargement >1 cm) stage of patients who only had biopsies without resections and the metastasis (M) stage of all patients. The tumor (T) and nodal (N) stages of all patients were determined in accordance with the 7th edition of the TNM UICC guidelines.<sup>11</sup>

### *Pathology*

All tumor samples were fixed in 10% formalin for 24 to 48 hours for histopathological and IHC evaluation. Histopathological assessment was performed on hematoxylin and eosin-stained tissue sections, cut in 4- $\mu$ m slices. Lauren's classification for gastric adenocarcinoma was used for histological subtyping (diffuse, intestinal, or mixed).<sup>12</sup> Glandular formation and cytologic pleomorphism were considered to histologically grade tumors as well, moderately, or poorly differentiated. Tumor differentiation (grade), necrosis, mitotic count (< or >5/high-power field [HPF], field diameter 0.65 mm), nuclear grade, presence of signet ring cells, extracellular mucin, and tumor inflammation with eosinophils were assessed in all tumors and documented in a structured data sheet. Additionally, the lymphocytic response at the tumor–host interface,

perineural invasion (PNI), lymphovascular invasion (LVI), muscle invasion, infiltrating tumor border, lymph node status, and pathological staging were assessed in gastric resections. A structured data sheet was used to document demographic and clinico-radiological-pathological features.

### **IHC**

Representative formalin-fixed, paraffin-embedded (FFPE) tumor tissue sections cut at 4  $\mu$ m were stained for HER2 protein expression by IHC. A polyclonal rabbit anti-human c-erbB-2 oncoprotein (Dako A0485; Agilent Technologies, Santa Clara, CA, USA) and Dako Real TM Envision system were used for IHC staining. Breast cancer tissue with HER2 +3 score by IHC was used as the positive control. HER2 IHC staining was interpreted following the scheme described by Ruschoff et al.<sup>13</sup> IHC scoring was performed by two independent pathologists. An IHC score of 0 or +1 was considered negative for HER2 overexpression, +2 was considered positive, and +3 was considered strongly positive.

### **SISH**

Tissue microarrays (TMAs) were prepared from 145 GC tissue blocks at the Department of Anatomical Pathology, Pathwest QE II Medical Centre, Perth, Australia. For the TMAs, two tissue cores with a diameter of 0.6mm were extracted from each tumor using the TMA arrayer (TMA Master 1.16 SP1). The tumor cores were sequentially placed in molds, embedded in paraffin, and cooled to form the tissue array blocks. Sections (4  $\mu$ m) obtained from the TMA blocks were used for SISH/IHC. The slides were stained using the Benchmark Ultraview automatic staining device (Ventana Medical Systems, Roche Diagnostics, Oro Valley, AZ, USA). HER2 SISH assessment was performed for the 145 GC cases using the

INFORM HER2 dual ISH DNA Probe Cocktail (Ventana Medical Systems). This was designed to use light microscopy to quantitatively detect amplification of the HER2 gene and the centromere portion of chromosome 17 (CEP17) via two color chromogenic ISH in FFPE human GC tissues. For SISH signal counting, a discrete signal was counted as a single copy of HER2 or CEP17. HER2 SISH signals (black) are typically smaller in size and more discrete in appearance than CEP17 SISH signals (red) because of differences in target size and detection chemistry. For signal interpretation, 20 cells were counted for red (CEP17) and black (HER2) signals. HER2 gene status was classified as non-amplified (HER2/CEP17 ratio <2.0) or amplified (HER2/CEP17 ratio  $\geq$ 2.0).

### **Data analysis**

SPSS Version 21 (IBM Corp., Armonk, NY, USA) was used for data analysis. The chi-square test was employed to identify associations between HER2 expression by IHC/SISH and clinicopathological features with a significance level of 5%. Haldane-Anscombe correction was used for calculating the effect measures when any cell in the contingency tables had a value of zero.

## **Results**

### **Patient demographics and tumor characteristics**

One hundred forty-five (145) consecutive GC patients were included in the study. Table 1 depicts the pathological characteristics and demographics of the GC study population. Many of the tumors (n = 72, 49.7%) were of Lauren's intestinal histological subtype, most (n = 87, 60%) were located in the proximal stomach, and over 60% of both proximal and distal GC tumors presented at an advanced (stage III/IV)

**Table 1.** Demographics and pathological characteristics of the study population of gastric carcinoma patients.

Lauren histological classification	Tumor location			Proximal (%)	Distal (%)	Total
	Intestinal (%)	Diffuse (%)	Mixed (%)			
<b>Sex</b>						
Male	49 (55.1)	24 (27)	16 (18)	53 (59.6)	36 (40.4)	89 (61.4%)
Female	23 (41.1)	18 (32.1)	15 (26.8)	34 (60.7)	22 (39.3)	56 (38.6%)
<b>Age (years)</b>						
>60	32 (47.8)	21 (31.3)	14 (20.9)	39 (58.2)	28 (41.8)	67 (46.2%)
≤60	40 (51.3)	21 (26.9)	17 (21.8)	48 (61.5)	30 (38.5)	78 (53.8%)
<b>Tumor stage</b>						
I	6 (40)	7 (46.7)	2 (13.3)	7 (46.7)	8 (53.3)	15 (10.3%)
II	22 (56.4)	9 (23.1)	8 (20.5)	25 (64.1)	14 (35.9)	39 (26.9%)
III	12 (48)	3 (12)	10 (40)	14 (56)	11 (44)	25 (17.2%)
IV	32 (48.5)	23 (34.8)	11 (16.7)	41 (62.1)	25 (37.9)	66 (45.5%)
<b>Tumor differentiation</b>						
Well	19 (50)	14 (36.8)	5 (13.2)	26 (68.4)	12 (31.6)	38 (26.2%)
Moderate	38 (67.9)	06 (10.7)	12 (21.4)	34 (60.7)	22 (39.3)	56 (38.6%)
Poor	15 (29.4)	<b>22 (43.1)</b>	14 (27.5)	27 (52.9)	24 (47.1)	51 (35.2%)
Total	72 (49.7%)	42 (28.9%)	31 (21.4%)	87 (60%)	58 (40%)	145 (100%)

radiological stage. Overall, 72 (49.6%), 42 (28.9%), and 31 (21.3%) cases were intestinal, diffuse, and mixed histological subtypes, respectively. Resected gastric specimens were primarily stage II (n = 35, 50.7%) for pathological staging (Table 1). Of the samples, 69 (47.6%) were gastric resections and 76 (52.4%) were endoscopic biopsies. There was a male predominance, with a male:female ratio of 1.6:1. The mean age at diagnosis was 60.06 years (range: 32 to 82 years).

### HER2 by IHC

HER2 expression was negative (0, +1) in the majority of cases (n = 133, 91.7%). Overall, there were 8.3% (12) HER2-positive cases by IHC (Score +2, moderate positivity, n = 7; Score +3, strong positivity, n = 5). Table 2 shows the correlations between the HER2 status by IHC score and the demographic, clinical, radiological, and pathological features of the GC cases.

### HER2 IHC expression and clinicopathological features

The comparison of clinicopathological features and HER2 IHC status by univariate analysis is shown in Tables 3 and 4. HER2-positive GC predominately occurred in those less than 60 years in age. Other clinicopathological features that were found to be significantly associated with HER2 positivity included higher T stage, higher nuclear grade, mitotic count >5/HPF, and the presence of tumor necrosis, PNI, and LVI in resections.

### HER2 by SISH

HER2 positivity assessed by SISH was 4.8% of cases (n = 7). All IHC +3 cases (n = 5) were SISH positive. Of the seven IHC +2 cases, SISH positivity was observed in only two cases. All IHC negative (0 and +1) cases (n = 133) were confirmed by SISH as negative (Figures 1–3, Tables 3 and 4).

**Table 2.** Human epidermal growth factor 2 (HER2) immunohistochemistry (IHC) score associations with demographics and clinical-radiological-pathological features of gastric carcinoma cases.

Demographic feature	HER2 IHC score				Total n (%)
	0 (%)	+1 (%)	+2 (%)	+3 (%)	
Age (years)					
≤60	55 (82)	3 (4.5)	4 (6)	5 (7.5)	67 (46.2)
>60	69 (88.5)	6 (7.7)	3 (3.8)	0 (0)	78 (53.8)
Sex					
Male	71 (80)	8 (9)	5 (5.5)	5 (5.5)	89 (61.4)
Female	53 (94.6)	1 (1.8)	2 (3.6)	0 (0)	56 (38.6)
Radiological/pathological					
TNM stage					
T1	6 (100)	0 (0)	0 (0)	0 (0)	6 (4.1)
T2	55 (90.2)	4 (6.6)	2 (3.2)	0 (0)	61 (42.1)
T3	30 (76.8)	1 (2.6)	4 (10.3)	4 (10.3)	39 (26.9)
T4	33 (84.6)	4 (10.2)	1 (2.6)	1 (2.6)	39 (26.9)
N0	46 (90.2)	4 (7.8)	1 (2)	0 (0)	51 (35.2)
N1	78 (83)	5 (5.3)	6 (6.4)	5 (5.3)	94 (64.8)
M0	69 (87.4)	6 (7.6)	2 (2.5)	2 (2.5)	79 (54.5)
M1	55 (83.3)	3 (4.5)	5 (7.7)	3 (4.5)	66 (45.5)
Radiological/pathological staging					
I	12 (80)	2 (13.3)	1 (6.6)	0 (0)	15 (10.3)
II	34 (87)	1 (2.6)	2 (5.2)	2 (5.2)	39 (26.9)
III	22 (88)	3 (12)	0 (0)	0 (0)	25 (17.2)
IV	56 (84.8)	3 (4.5)	4 (6.2)	3 (4.5)	66 (45.6)
Type of specimen					
Biopsy	66 (86.8)	3 (3.9)	4 (5.4)	3 (3.9)	76 (52.4)
Resection	58 (84)	6 (8.7)	3 (4.3)	2 (3)	69 (47.6)
Tumor location					
Proximal	75 (86.2)	6 (6.9)	4 (4.6)	2 (2.3)	87 (60)
Distal	49 (84.4)	3 (5.2)	3 (5.2)	3 (5.2)	58 (40)
Lauren histological type					
Intestinal	67 (93)	1 (1.4)	2 (2.8)	2 (2.8)	72 (49.7)
Diffuse	32 (76.2)	4 (9.5)	4 (9.5)	2 (4.8)	42 (28.9)
Mixed	25 (80.6)	4 (13)	1 (3.2)	1 (3.2)	31 (21.4)
Tumor differentiation (grade)					
Well	32 (84.2)	2 (5.2)	2 (5.2)	2 (5.2)	38 (26.2)
Moderate	50 (89.3)	4 (7.1)	2 (3.6)	0 (0)	56 (38.6)
Poor	42 (82.3)	3 (5.9)	3 (5.9)	3 (5.9)	51 (35.2)
Nuclear grade					
Low	71 (88.7)	6 (7.5)	3 (3.8)	0 (0)	80 (55.2)
High	53 (81.5)	3 (4.6)	4 (6.2)	5 (7.7)	65 (44.8)
Tumor necrosis					
Present					
Focal	11 (64.6)	2 (11.8)	2 (11.8)	2 (11.8)	17 (11.7)
Extensive	4 (66.7)	0 (0)	2 (33.3)	0 (0)	6 (04.1)

(continued)

**Table 2.** Continued.

Demographic feature	HER2 IHC score				Total
	0 (%)	+1 (%)	+2 (%)	+3 (%)	n (%)
Absent	109 (89.3)	7 (5.7)	3 (2.5)	3 (2.5)	122 (84.2)
Mitotic count					
>5/HPF	37 (75.6)	3 (6.1)	6 (12.2)	3 (6.1)	49 (33.8)
<5/HPF	87 (90.6)	6 (6.2)	2 (2.1)	1 (1.1)	96 (66.2)
Signet cells					
Present	48 (77.4)	8 (12.9)	4 (6.5)	2 (3.2)	62 (42.7)
Absent	76 (91.6)	1 (1.2)	3 (3.6)	3 (3.6)	83 (57.2)
Extracellular mucin					
Present	20 (66.7)	6 (20)	3 (10)	1 (3.3)	30 (20.7)
Absent	104 (90.4)	3 (2.6)	4 (3.5)	4 (3.5)	115 (79.3)
Tumor inflammation with eosinophils					
Present	9 (90)	0 (0)	0 (0)	1 (10)	10 (6.9)
Absent	115 (85.2)	9 (6.7)	7 (5.2)	4 (2.9)	135 (93.1)
Lymphocytic response at tumor host interface (in resections)					
Present	33 (97.1)	1 (2.9)	0 (0)	0 (0)	34 (49.3)
Absent	25 (71.4)	5 (14.3)	3 (8.6)	2 (5.7)	35 (50.7)
Perineural invasion (in resections)					
Present	18 (75)	2 (8.3)	2 (8.3)	2 (8.3)	24 (34.8)
Absent	40 (88.9)	4 (8.9)	1 (2.2)	0 (0)	45 (65.2)
Lymphovascular invasion (in resections)					
Present	21 (77.8)	1 (3.7)	3 (11.1)	2 (7.4)	27 (39)
Absent	37 (88.1)	5 (11.9)	0 (0)	0 (0)	42 (61)
Muscle invasion (in resections)					
Present	51 (85)	4 (6.7)	3 (5)	2 (3.3)	60 (87)
Absent	7 (77.8)	2 (22.2)	0 (0)	0 (0)	<b>09 (13)</b>
Infiltrating border (in resections)					
Present	39 (86.7)	3 (6.7)	2 (4.4)	1 (2.2)	45 (65.2)
Absent	19 (79.2)	3 (12.4)	1 (4.2)	1 (4.2)	24 (34.8)
Total	124 (85.5)	9 (6.2)	7 (4.8)	5 (3.5)	145 (100)

HPF, high-power field.

The results of the univariate analysis of the correlations between clinicopathological features and HER2 status by SISH are shown in Tables 5 and 6. The clinicopathological features found to be significantly associated with HER2 positivity included age less than 60 years, male sex, higher T stage (>T3), higher nuclear grade, higher mitotic count (>5/HPF), extracellular mucin, and the presence of tumor necrosis, PNI, and LVI in resections.

## Discussion

This is the first study conducted in a Sri Lankan setting that reports the potential predictors of HER2 status using SISH. Here, we found 4.8% of cases to be HER2-positive by SISH and 8.3% to be HER2-positive by IHC. Age less than 60 years, higher T stage (>T3), higher nuclear grade, mitotic count >5/HPF, and the presence of tumor necrosis, PNI, and

**Table 3.** Comparison of clinicopathological features and human epidermal growth factor 2 (HER2) immunohistochemistry (IHC) status (N = 145; univariate analysis).

Variables	Positive (Total = 12) N (%)	Negative (Total = 133) N (%)	Total N (%)	Association P-value or OR (95% CI)
Age (years)				
>60	2 (2.5)	78 (97.5)	80 (100.0)	<b>0.005*</b>
≤60	10 (15.4)	55 (84.6)	65 (100.0)	0.14 (0.03–0.67)
Sex				
Male	10 (11.2)	79 (88.8)	89 (100.0)	0.129 <sup>e</sup>
Female	2 (3.5)	54 (96.4)	56 (100.0)	3.42 (0.72–16.22)
Primary tumor stage (T)**				
T1–2	2 (2.9)	65 (97.1)	67 (100.0)	<b>0.032*</b>
T3–4	10 (12.8)	68 (87.2)	78 (100.0)	0.21 (0.04–0.99)
Regional lymph nodes (N)**				
N0	2 (3.4)	56 (95.6)	58 (100.0)	0.124
N1	10 (11.5)	77 (88.5)	87 (100.0)	0.28 (0.06–1.30)
Distant metastases (M)#				
M0	4 (5.1)	75 (94.9)	79 (100.0)	0.125
M1	8 (1.2)	58 (87.8)	66 (100.0)	0.39 (0.11–1.35)
Radiological/pathological tumor stage (T)				
I or II	5 (9.3)	49 (90.7)	54 (100.0)	0.762 <sup>e</sup>
III or IV	7 (7.7)	84 (92.3)	91 (100.0)	1.22 (0.37–4.07)
Tumor location				
Proximal	6 (6.9)	81 (93.1)	87 (100.0)	0.544 <sup>e</sup>
Distal	6 (10.3)	52 (89.7)	58 (100.0)	0.64 (0.20–2.10)
Lauren histological classification				
Intestinal	4 (5.6)	68 (94.4)	72 (100.0)	0.238
Diffuse or mixed	8 (10.9)	65 (89.1)	73 (100.0)	0.48 (0.14–1.66)
Tumor differentiation (grade)				
Well	4 (10.5)	34 (89.5)	38 (100.0)	0.732 <sup>e</sup>
Moderate or poor	8 (7.4)	99 (92.6)	107 (100.0)	1.46 (0.41–5.14)
Nuclear grade				
Low	3 (3.7)	77 (96.3)	80 (100.0)	<b>0.028*</b>
High	9 (13.8)	56 (86.2)	65 (100.0)	0.24 (0.06–0.94)
Mitotic count				
<5/HPF	4 (4.2)	92 (95.8)	96 (100.0)	<b>0.022<sup>e*</sup></b>
>5/HPF	8 (16.3)	41 (83.7)	49 (100.0)	0.22 (0.06–0.78)
Signet ring cells				
Yes	6 (9.7)	56 (90.3)	62 (100.0)	0.597
No	6 (7.2)	77 (92.8)	83 (100.0)	1.38 (0.42–4.49)
Extracellular mucin				
Yes	4 (13.3)	26 (86.7)	30 (100.0)	0.249 <sup>e</sup>
No	8 (7)	107 (93)	115 (100.0)	2.25 (0.63–8.04)

\*Significant P-value; <sup>e</sup>Exact significance; \*\*Clinicoradiological in biopsies and pathological in gastric resections; # radiological; OR, odds ratio; CI, confidence interval; HPF, high-power field.



**Table 4.** Comparisons of clinicopathological features and human epidermal growth factor 2 (HER2) immunohistochemistry (IHC) status in resection samples (N = 69; univariate analysis).

Variable	Positive (Total = 5) N (%)	Negative (Total = 64) N (%)	Total N (%)	Association P-value or OR (95% CI)
Lymph node metastasis (pN)				
N0	0 (0)	14 (100)	14 (100.0)	0.363 <sup>e</sup>
N1	5 (9)	50 (91)	55 (100.0)	0.32 (0.02–6.07) <sup>h</sup>
Tumor necrosis				
Yes	4 (28.6)	10 (71.4)	14 (100.0)	<b>0.005<sup>e*</sup></b>
No	1 (1.8)	54 (98.8)	55 (100.0)	21.60 (2.18–213.90)
Tumor inflammation with eosinophils				
Present	0 (0)	5 (100)	5 (100.0)	1.000 <sup>e</sup>
Absent	5 (7.8)	59 (92.2)	4 (100.0)	1.07 (0.05–213.92) <sup>h</sup>
Tumor inflammation with lymphocytic response				
Present	0 (0)	34 (100)	4 (100.0)	0.054 <sup>e</sup>
Absent	5 (14.3)	30 (85.7)	5 (100.0)	0.08 (0.004–1.51) <sup>h</sup>
Perineural invasion				
Yes	5 (26.3)	14 (73.7)	19 (100.0)	<b>0.001<sup>e*</sup></b>
No	0 (0)	50 (100)	50 (100.0)	38.31 (1.99–734.46) <sup>h</sup>
Lymphovascular invasion				
Yes	5 (20)	20 (80)	25 (100.0)	<b>0.005<sup>e*</sup></b>
No	0 (0)	44 (100)	44 (100.0)	23.88 (1.26–452.58) <sup>h</sup>
Muscle invasion				
Yes	5 (8.3)	55 (91.7)	60 (100.0)	0.609 <sup>e</sup>
No	0 (0)	9 (100)	9 (100.0)	1.88 (0.10–36.91) <sup>h</sup>
Infiltrating border				
Present	3 (6.7)	42 (93.3)	45 (100.0)	1.000 <sup>e</sup>
Absent	2 (8.3)	22 (91.7)	24 (100.0)	0.79 (0.12–5.06)


\*Significant P-value; <sup>e</sup>Exact significance; <sup>h</sup>Haldane-Anscombe correction; OR, odds ratio; CI, confidence interval.

LVI in resections were predictors of both IHC and SISH HER2 positivity. Additionally, male sex was a predictor of SISH HER2 positivity. This study helps identify potential predictors of HER2 status in lower-to-middle income settings, like Sri Lanka, where further confirmatory testing by ISH is not routinely available.


Notably, most studies that analyzed HER2 expression levels and clinicopathological features involved patients who had undergone curative resections.<sup>9,13,14</sup> Recent advances in understanding the GC disease process from both biological and genomic perspectives have brought target-oriented therapy for advanced GC cases into clinical

research and practice. The present study included a significant number of participants with advanced GC. It is essential to explore this subgroup of patients with advanced GC because they are the targeted subset that is eligible for trastuzumab.

HER2 testing in GC is an evolving area of clinical practice that has particular relevance to Asia-Pacific countries, which face a high incidence of this disease.<sup>3</sup> Data on HER2 expression in Sri Lankan GC patients are very limited. An earlier study conducted and published in Sri Lanka found a HER2 overexpression rate of 9% by IHC.<sup>6</sup> In the present study, we determined HER2 positivity rates using IHC




**Figure 1.** Human epidermal growth factor 2 (HER2)-positive gastric carcinoma (GC). (a) Moderately HER2-positive (+2) GC analyzed by immunohistochemistry (IHC) with normal surrounding gastric tissue (20 $\times$ ). (b) IHC HER2+ 2 GC (40 $\times$ ). (c) Silver in situ hybridization (SISH)-amplified GC with adjacent non-amplified normal gastric tissues and (d) SISH amplification of IHC HER2 + 2 GC.



**Figure 2.** Human epidermal growth factor 2 (HER2)-positive gastric carcinoma by immunohistochemistry (strongly positive (+3) tumor (20 $\times$ )).

and SISH, both of which were lower than 9%. The reasons for this are likely multifactorial. In most studies,<sup>9,14</sup> the study sample was a mixture of GOJ and gastric carcinomas.



**Figure 3.** Human epidermal growth factor 2 (HER2)-positive gastric carcinoma by silver in situ hybridization (SISH). This is tumor is strongly positive by HER2 immunohistochemistry (+3). SISH showed strong amplification with nuclear clumps (20 $\times$ ).

**Table 5.** Comparison of clinicopathological features and human epidermal growth factor 2 (HER2) silver in situ hybridization (SISH) status (N = 145).

Variables	Positive N (%)	Negative N (%)	Total N (%)	Association P-value or OR (95% CI)
Age (years)				
>60	1 (1.3)	79 (98.7)	80 (100.0)	<b>0.045<sup>e*</sup></b>
≤60	6 (9.2)	59 (90.8)	65 (100.0)	0.12 (0.02–1.06)
Sex				
Male	7 (7.9)	82 (92.1)	89 (100.0)	<b>0.043<sup>e*</sup></b>
Female	0 (0)	56 (100)	56 (100.0)	10.27 (0.56–183.50)
Primary tumor stage (T)				
T1–2	0 (0)	67 (100)	67 (100.0)	<b>0.015<sup>e*</sup></b>
T3–4	7 (9)	71 (91)	78 (100.0)	0.07 (0.004–1.26)
Regional lymph nodes (N)				
N0	0 (0)	58 (100)	58 (100.0)	<b>0.042<sup>e*</sup></b>
N1	7 (8)	80 (92)	87 (100.0)	0.08 (0.004–1.44)
Distant metastases (M)				
M0	2 (2.5)	77 (97.5)	79 (100.0)	0.246
M1	5 (7.6)	61 (92.4)	66 (100.0)	0.32 (0.06–1.69)
Radiological/pathological tumor stage (T)				
I or II	3 (5.6)	51 (94.4)	54 (100.0)	1.000 <sup>e</sup>
III or IV	4 (4.4)	87 (95.6)	91 (100.0)	1.28 (0.28–5.95)
Tumor location				
Proximal	4 (4.6)	83 (95.4)	87 (100.0)	1.000 <sup>e</sup>
Distal	3 (5.2)	55 (94.8)	58 (100.0)	0.88 (0.19–4.10)
Lauren histological classification				
Intestinal	3 (4.2)	69 (95.8)	72 (100.0)	1.000 <sup>e</sup>
Diffuse or mixed	4 (5.5)	69 (94.5)	73 (100.0)	0.75 (0.16–3.48)
Tumor differentiation (grade)				
Well	3 (7.9)	35 (92.1)	38 (100.0)	0.379 <sup>e</sup>
Moderate or poor	4 (3.7)	103 (96.3)	107 (100.0)	2.21 (0.47–10.35)
Nuclear grade				
Low	1 (1.2)	79 (98.8)	80 (100.0)	<b>0.045<sup>e*</sup></b>
High	6 (9.2)	59 (90.8)	65 (100.0)	0.12 (0.02–1.06)
Mitotic count				
<5/HPF	2 (2.1)	94 (97.9)	96 (100.0)	<b>0.044<sup>e*</sup></b>
>5/HPF	5 (10.2)	44 (89.8)	49 (100.0)	0.19 (0.04–1.003)
Signet ring cells				
Yes	3 (4.8)	59 (95.2)	62 (100.0)	1.000 <sup>e</sup>
No	4 (4.8)	79 (95.2)	83 (100.0)	1.004 (0.22–4.66)
Extracellular mucin				
Yes	6 (17.1)	29 (82.9)	35 (100.0)	<b>&lt;0.001<sup>e*</sup></b>
No	1 (0.9)	109 (99.1)	110 (100.0)	22.55 (2.6–194.82)

\*Significant P-value; <sup>e</sup>Exact significance; <sup>h</sup>Haldane-Anscombe correction; OR, odds ratio; CI, confidence interval; HPF, high-power field.

**Table 6.** Comparison of clinicopathological features and human epidermal growth factor 2 (HER2) silver in situ hybridization (SISH) status in resection samples (N = 69).

Variable	Positive (Total = 3) N (%)	Negative (Total = 66) N (%)	Total	Association P-value or OR (95% CI)
Lymph node metastasis (pN)				
N0	0 (0)	14 (100.0)	14 (100.0)	0.603 <sup>e</sup>
N1	3 (5.5)	52 (94.5)	55 (100.0)	0.55 (0.03–11.19) <sup>h</sup>
Tumor necrosis				
Yes	3 (21.4)	11 (78.6)	14 (100.0)	<b>0.007</b> <sup>*e</sup>
No	0 (0)	55 (100)	55 (100.0)	33.78 (1.63–699.57) <sup>h</sup>
Tumor inflammation with eosinophils				
Present	0 (0)	5 (100)	5 (100.0)	1.000 <sup>e</sup>
Absent	3 (4.7)	61 (95.3)	64 (100.0)	1.60 (0.07–35.07) <sup>h</sup>
Tumor inflammation with lymphocytic response				
Present	0 (0)	34 (100)	34 (100.0)	0.077 <sup>e</sup>
Absent	3 (8.6)	32 (91.4)	35 (100.0)	0.10 (0.005–2.00) <sup>h</sup>
Perineural invasion				
Yes	3 (15.8)	16 (84.2)	19 (100.0)	<b>0.018</b> <sup>*e</sup>
No	0 (0)	50 (100)	50 (100.0)	21.42 (1.05–436.78) <sup>h</sup>
Lymphovascular invasion				
Yes	3 (12)	22 (88)	25 (100.0)	<b>0.043</b> <sup>*e</sup>
No	0 (0)	44 (100)	44 (100.0)	13.84 (0.68–279.83) <sup>h</sup>
Muscle invasion				
Yes	3 (5)	57 (95)	60 (100.0)	1.000 <sup>e</sup>
No	0 (0)	9 (100)	9 (100.0)	1.16 (0.06–24.22) <sup>h</sup>
Infiltrating border				
Present	1 (2.2)	44 (97.8)	45 (100.0)	0.275 <sup>e</sup>
Absent	2 (8.4)	22 (91.6)	44 (100.0)	0.25 (0.02–2.91)

\*Significant P-value; <sup>e</sup>Exact significance; <sup>h</sup>Haldane-Anscombe correction; OR, odds ratio; CI, confidence interval.

Generally, GOJ tumors are reported to have higher HER2 positivity.<sup>15</sup>

Until recently, no significant relationships between clinicopathological features of age, sex, pTNM, differentiation, or location with HER2 positivity have been documented in the literature.<sup>14,16–19</sup> According to many studies,<sup>20–23</sup> the intestinal type showed a higher rate of HER2 positivity than the diffuse type. In contrast, a recent meta-analysis<sup>24</sup> concluded that HER2-positive expression was associated with male sex, intestinal type, and well/moderate cell differentiation. This meta-analysis involved 15 studies (original articles), including 5990

gastric resections, that were analyzed to identify the clinicopathological factors associated with HER2 positivity. No relationship was observed between HER2 positivity and depth of tumor invasion, venous invasion, or lymphatic invasion. In the present study, younger age (<60 years) was significantly associated with both IHC ( $P=0.005$ , OR = 0.14, 95% CI = 0.03–0.67) and SISH ( $P=0.045$ , OR = 0.12, 95% CI = 0.02–1.06) HER2 positivity. This requires further examination with prospective analytical studies.

Both IHC and SISH HER2 positivity were significantly associated with higher T stage (T3, T4) ( $P=0.032$  for IHC,  $P=0.015$  for

SISH). Sex ( $P=0.043$ ) also showed a significant association with HER2 positivity by SISH.

The intestinal subtype has been demonstrated in multiple studies to be the pathological feature that is invariably associated with HER2 positivity,<sup>9,14,25–33</sup> including the ToGA trial.<sup>9</sup> In the present study, HER2 positivity was observed by SISH equally in the intestinal and diffuse types. One mixed tumor showed positive HER2 expression in the intestinal component. Therefore, HER2 expression was more commonly observed in the intestinal type cases, which is compatible with the previous findings. In our study, 72 (49.6%), 42 (28.9%), and 31 (21.3%) cases were intestinal, diffuse, and mixed histological subtypes, respectively. Interestingly, nearly 29% of tumors in the present study were diffuse, and the intestinal type was not significantly associated with HER2 overexpression.

According to Taghavi et al.,<sup>34</sup> HER2 overexpression has no impact on disease prognosis, while other literature has provided contradictory evidence.<sup>35,36</sup> Only a few studies have assessed the association of PNI with HER2 in GC, which concluded that there is no significant association between PNI and HER2 status.<sup>37–42</sup> PNI is an underexplored phenomenon in GC, and its clinical significance remains controversial.<sup>43</sup> In the present study, PNI and high nuclear grade were significant predictors of HER2 expression by IHC and SISH. Most large-scale studies<sup>23,24,44</sup> have not explored the association of tumor necrosis, PNI, or higher nuclear grade with HER2 overexpression. Tumor necrosis was also a significant predictor of HER2 expression in the present study. This highlights the necessity for further analytical studies regarding these predictors.

There are several methodological limitations to this study. First, the number of HER2-positive IHC cases was not sufficient to employ multivariate analysis to obtain cofounder-adjusted clinicopathological

estimates of HER2 IHC. Therefore, this analysis was restricted to bivariable analysis. Second, the study included a notable number of biopsies, as the number of gastric resections was relatively low because of the advanced stage of disease presentation in this setting. This was considered during data analysis and interpretation.

## Conclusions

Our results suggest that LVI ( $P=0.043$ ), tumor necrosis ( $P=0.007$ ), and PNI ( $P=0.018$ ) in resections are the histopathological factors associated with HER2 positivity by SISH. Combined with the demographic associated factor of age, these three factors could potentially be used as screening parameters for HER2 testing in limited resource settings and would be of value for future patient management. With further robust evidence generated from future analytical studies, incorporation of these features to develop a scoring system to predict HER2 positivity is possible and would be cost effective for limited resource settings. An accurate and reliable scoring system, together with clinical information, may help us to better determine whether a patient with GC is a potential candidate for HER2-based targeted therapy.

## Acknowledgements

The authors thank Mrs. G. K. Wijesinghe (staff technical officer) for technical assistance with laboratory work and Dr. Medhavini Dissanayake and Dr. Sameera Ravishan for assistance with data collection.

## Author contributions

DS and MDSL designed the study with contributions from PKBM, SM, MPK, SS, and DNS. DS was involved in laboratory work, data collection and analysis, and writing the manuscript. NA supervised SISH laboratory work. MPK supervised and provided expertise in SISH interpretation. PKBM and SM provided expert statistical input. MDSL critically evaluated and

edited the manuscript. All authors read and approved the final manuscript.

### Declaration of conflicting interest

The authors declare that there is no conflict of interest.

### Funding

This study was funded by The National Research Council, Sri Lanka (NRC grant 11-100) and The National Science Foundation (NSF, Grant No. OSTP/2016/03).

### ORCID iD

Duminda Subasinghe  <https://orcid.org/0000-0003-1805-1589>

### References

- Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin* 2011; 61: 69–90.
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359–E386.
- Kamangar F, Dores GM and Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006; 24: 2137–2150.
- Power DG, Kelsen DP and Shah MA. Advanced gastric cancer—slow but steady progress. *Cancer Treat Rev* 2010; 36: 384–392.
- Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. *Cochrane Database Syst Rev* 2010; 17: CD004064.
- Subasinghe D, Sivaganesh S, Samarsekera A, et al. Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival. *Dig Dis Sci* 2017; 62: 2498–2510. doi: 10.1007/s10620-017-4647-2.
- Siriwardana HDRC and Pathirana A. Adenocarcinoma of the stomach in a tertiary care hospital in Sri Lanka. *Ceylon Medical Journal* 2007; 52: 53–55.
- Kim KM, Bilous M, Chu KM, et al. Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. *Asia Pac J Clin Oncol* 2014; 10: 297–307.
- Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; 376: 687–697.
- Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147: 573–577.
- Sobin LH, Gospodarowicz M and Wittekind C. *TNM Classification of Malignant Tumours*. 7th ed. Wiley-Blackwell, Oxford 2009.
- Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965; 64: 31–49.
- Rüschhoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. *Virchows Arch* 2010; 457: 299–307.
- Shan L, Ying J and Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. *Diagn Pathol* 2013; 8: 76. doi: 10.1186/1746-1596-8-76.
- Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer* 2015; 18: 476–484. doi: 10.1007/s10120-014-0402-y.
- Boers JE, Meeuwissen H and Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). *Histopathology* 2011; 58: 383–394.
- Grillo F, Fassan M, Sarocchi F, et al. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. *World J Gastroenterol* 2016; 22: 5879–5887.

18. Yan SY, Hu Y, Fan JG, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. *World J Gastroenterol* 2011; 17: 1501–1506.
19. Chen B, Luo RC, Cui F, et al. Association of HER-2/neu expression with prognosis of gastric cancer. *Nan Fang Yi Ke Da Xue Bao* 2006; 26: 344–347.
20. Kunz PL, Mojtahed A, Fisher GA, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. *Appl Immunohistochem Mol Morphol* 2012; 20: 13–24.
21. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. *Human Pathol* 2007; 38: 1386–1393.
22. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. *J Clin Pathol* 2010; 63: 839–842.
23. Jørgensen JT and Hersom M. HER2 as a Prognostic Marker in Gastric Cancer – A Systematic Analysis of Data from the Literature. *J Cancer* 2012; 3: 137–144.
24. Wang HB, Liao XF and Zhang J. Clinicopathological factors associated with HER2-positive gastric cancer A meta-analysis. *Medicine (Baltimore)* 2017; 96: e8437.
25. Laboissiere RS, Buzelin MA, Balabram D, et al. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. *BMC Gastroenterol* 2015; 15: 157.
26. Cho J, Jeong J, Sung J, et al. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. *Ann Surg Oncol* 2013; 20: S477–S484.
27. Cappellesso R, Fassan M, Hanspeter E, et al. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. *Hum Pathol* 2015; 46: 665–672.
28. Matsusaka S, Nashimoto A, Nishikawa K, et al. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). *Gastric Cancer* 2015; 19: 839–851. [Epub ahead of print].
29. Kataoka Y, Okabe H, Yoshizawa A, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. *Gastric Cancer* 2013; 16: 84–93.
30. Cruz-Reyes C and Gamboa-Dominguez A. HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype. *Int J Surg Pathol* 2013; 21: 240–246.
31. Begnami MD, Fukuda E, Fregnani JH, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. *J Clin Oncol* 2011; 29: 3030–3036.
32. Jácome AA, Wohnrath DR, Scapulatempo Neto C, et al. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. *Gastric Cancer* 2014; 17: 76–86.
33. De Carli DM, Rocha MP, Antunes LC, et al. Immunohistochemical expression of her2 in adenocarcinoma of the stomach. *Arq Gastroenterol* 2015; 52: 152–155.
34. Taghavi S, Jayarajan SN, Davey A, et al. Prognostic significance of signet ring cell gastric cancer. *J Clin Oncol* 2012; 30: 3493–3498.
35. Pernet S, Voron T, Perkins G, et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. *World J Gastroenterol* 2015; 21: 11428–11438.
36. Kwon KJ, Shim KN, Song EM, et al. Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. *Gastric Cancer* 2015; 17: 43–53.
37. Chua TC and MerrettInt ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—A systematic review. *Int J Cancer* 2012; 130: 2845–2856.
38. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. *Dig Dis Sci* 2006; 51: 1371–1379.

39. Song HS, Do YR, Kim IH, et al. Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. *Cancer Res Treat* 2004; 36: 240–245.
40. Garcia I, Vizoso F, Martin A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. *Ann Surg Oncol* 2003; 10: 234–241.
41. Gupta P, Rao S and Bhalla S. Human epidermal growth factor receptor 2 expression in gastric carcinoma and its association with histopathological parameters in Indian population. *Indian J Cancer* 2016; 53: 505–511.
42. Laboissiere RS, Buzelin MA, Balabram D, et al. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. *BMC Gastroenterology* 2015; 15: 157.
43. Liebig C, Ayala G, Wilks JA, et al. Perineural invasion in cancer: a review of the literature. *Cancer* 2009; 115: 3379–3391.
44. Matsusaka S, Nashimoto A, Nishikawa K, et al. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). *Gastric Cancer* 2016; 19: 839–851.